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Topical Review
Risk factors for neuropathic pain in
diabetes mellitus
Harry L. He´bert*, Abirami Veluchamy, Nicola Torrance, Blair H. Smith
1. Introduction
According to the International Diabetes Federation, diabetes
mellitus (DM) is estimated to affect around 415 million adults
worldwide, roughly 8.8% of the adult population, with the figure
projected to rise to over 600 million by 2040.20 Regional
prevalence varies from 3.2% in Africa to 12.9% in North America.
Diabetesmellitus is associatedwith a number of chronic sequelae
and around 50% of people with DM go on to develop
polyneuropathy.35 This condition has a variety of clinical
manifestations, which are grouped into positive symptoms
including dysesthesia (abnormal sense of touch), tingling and
itching, and negative symptoms including numbness, muscle
weakness, and trouble with balance. Up to 25% of people with
diabetic neuropathy (DN) also develop neuropathic pain (NP).39
Neuropathic pain is defined by the International Association for
The Study of Pain as “pain directly caused by a lesion or disease
affecting the somatosensory system.”12,22 Symptoms of painful
diabetic neuropathy (PDN) include those described above for
nonpainful DN with additional “burning,” “electric shocks,”
“stabbing,” and “pins and needles” symptoms all being de-
scribed. Painful diabetic neuropathy is associated with increased
distress and poor quality of life compared with nonpainful DN,
DM, and the general population38 including depression, anxiety,
and sleep disturbance.15 In addition, an association has been
described with reduced productivity and employability at work
compared with nonpainful DN.37 The combination of these
factors places a large economic burden on patients and health
care services,10 a situation likely to grow steadily worse with the
aforementioned projected rise in DM prevalence. This situation is
further exacerbated by the fact that 13% of patients with PDN do
not report their symptoms to primary care, and 39% of patients
with PDN have never received treatment.8 Even for those patients
whodo attend primary and secondary care for their diabetes, pain
is not a symptom that is always included in clinical assessments.
Furthermore, not all patients with DN develop PDN, and the
reasons for this are unclear.
Understanding the risk factors for PDN will go some way to
resolving this and will also help to inform management and
prevention of this painful condition by health care services. Any
factor that increases the risk of DM or DN is likely to be a risk
factor for PDN. However, it is the specific nature and magnitude
of the risk that remains unclear and is the focus of this topical
review.
2. Risk factors
There have been relatively few published studies examining risk
factors specifically for PDN in DM. Clinical, environmental, and
genetic factors have been shown to be predictive of developing
DM and some of these have also been implicated in the
development of DN, including age,11 body mass index,25,28
hypertension,13 smoking, and waist circumference28 (Fig. 1).
Given the likely overlap of risk factors between DM and DN, it
seems reasonable to hypothesize that some of these factors will
also influence the development of PDN.
We conducted a literature search using relevant key words and
terms aiming to identify a wide range of studies that investigated
risk factors for PDN and to include all the important studies
(Table 1). A number of limitations can be identified with these
studies as a whole. Most of these studies are cross sectional in
nature and therefore unable to establish temporal relationship
between patient characteristics/factors and PDN. Some studies
report only univariate analysis and are therefore unable to assess
intervariable relationships and to identify confounding between
variables.2,6,8,9,17,23,30 In addition, it is not always clear in the
methods and statistical analyses whether PDN or nonpainful DN
is being analysed and what control group the PDN subjects are
being compared with. In some studies, those in the control group
are diabetic participants with nonpainful neuropathy30,38,41 and in
others they are diabetic participants without neuropathy of any
form.1,2,6,8,11,17 In other studies, it is not possible to determine the
nature of the control group from the description of the methods.
There was considerable heterogeneity in PDN case ascertain-
ment, with only 6 studies using a validated NP screening
questionnaire (the DN46,7,17,21,38 or the Leeds assessment of
neuropathic symptoms and signs11) with the remainder using
nonvalidated questionnaires or clinical examinations. This makes
it difficult to assess the sensitivity and specificity of each study to
identify PDN cases and to make direct comparisons between
studies as effect size estimations and associations are likely to be
different. Despite these limitations, some potential risk factors
have emerged, including environment, clinical, lifestyle, and
genetic factors.
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2.1. Demographic
Two nonmodifiable factors—age2,17,21,38,42 and sex1,11,17,21,41—
have been specifically associated with PDN, in addition to their
known roles as risk factors for DM. Although these are of limited
use to clinicians in terms of intervention, they could provide useful
clues as to the underlying biological pathways involved and
increased awareness of at-risk patients. In particular, the
association of PDN with older age (.50 years) is likely to be
related to the time it takes for nerve damageandpainful symptoms
to develop after the onset of DM and the decreased ability of the
body to deal with this. Similarly, gender associations may indicate
possible subtle differences in biology and psychosocial factors
that affect the risk of PDN, something that requires further
investigation. It is interesting to note that while 4 of the studies
report greater risk in women,1,11,17,21 1 study reports greater risk
in men.41 This discrepancy in the latter study could be related to
the limited statistical analysis, which did not adjust for potential
confounding factors. Despite the prevalence of DM varying
according to ethnicity, this has not been found as a risk factor
so far for PDN.1,17,18,21,32,36 One study reported that South Asians
were more likely to report painful symptoms than people in other
ethnic groups in the absence of clinical neuropathy.1 Another
found an association with pain among people with DM residing in
a Gulf state and Lebanon compared with Egypt, but did not
analyse ethnic origin.21
2.2. Clinical
Clinical and physiological factors associated with PDN are
important for clinicians and primary care as they may indicate
possibilities for targeted treatment or primary prevention strategies.
The clinical diagnosis of the type of DM and the duration since
onset of the disease may be particularly relevant. Two studies
found an association with DM type in multivariate analysis, with 1
identifying type 1 diabetes (T1D)21 and the other type 2 diabetes
(T2D)1 as conferring greater risk of PDN. Differences in case
definition and study populations could have contributed to the
heterogeneity in these results. A clearer consensus is apparent for
DM duration with risk increasing over time since diagno-
sis.2,6,17,21,32,38 Severity of preceding neuropathy has been found
to be associated with PDN, but associations with neuropathy
duration and comparison with type of (peripheral or sensory)
neuropathy have not been found.9,11,33,36 Most studies included
only 1 type of neuropathy in their analysis. A number of clinical
factors and comorbidities have been found to be associated with
PDN. These include poor glycaemic control and high HbA1c
levels,2,18,36 hypertension,2,18 retinopathy,2 nephropathy,2,38 car-
diovascular disease,2,42,43 and glycosuria.18 However, as these
conditions are all known complications of DM, it is uncertain from
cross-sectional analysis whether these factors are contributing to
PDN risk and onset, or simply coexisting factors, perhaps
confounded by other factors or with shared aetiology. Biomarkers
for the development of PDN can be exploited by providing
preventative or diagnostic tests. In this respect, tumour necrosis
factor alpha and inducible nitric oxide synthase expression,30
triglycerides, and low high-density lipoprotein cholesterol38 all
showpromising associationsbut require replication to be confident
in their role in disease pathogenesis.
2.3. Lifestyle
Behavioural and social circumstances are important lifestyle
aspects that patients can theoretically influence and act on, with
greater or less practical difficulty. In particular, some physical
characteristics known to be associated with DM and DN are also
implicated in PDN. Body mass index has been clearly linked to
PDN, particularly in the form of obesity ($30 kg/m2),21,33,38 while in
another study, weight was reported independently of height and
found to be significantly associated with PDN, although this was
attenuated in multivariate analysis.42 A related study also found
a positive correlation with increased waist circumference and high
levels of physical activity and risk of PDN.43 Despite being included
in the analyses in most of the studies,1,2,4,8,17,18,21,32,33,38,42,43
smoking and alcohol consumption have not been specifically
associated with PDN. Psychological factors have also been widely
reported in the context of general chronic pain, but its relationship
with PDN is less clear. Increased depression, anxiety, enjoyment of
life, and social relationships are associated with PDN, but without
prospective studies and longitudinal analysis, the temporal re-
lationship cannot be established.7,15
Figure 1. Schematic of the process from diabetes mellitus to diabetic neuropathy and finally painful diabetic neuropathy. Both diabetes mellitus and diabetic
neuropathy have their own set of risk factors, both of which could provide important clues as to the risk factors that contribute to painful diabetic neuropathy.
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Table 1
List of studies conducted on predictors of painful diabetic neuropathy and their characteristics.
Reference Study type Population Criteria for NP Sample size Analysis Variables analysed Predictors OR (95% CI)/P
Abbott et al.,
20111
Cross sectional UK NSS $ 5 and NDS $ 3 3242 DM with NP Multivariate logistic
regression
Age, alcohol, diabetes duration,
diabetes treatment, diabetes
type, ethnicity, foot ulcer, foot
deformities, impaired vision,
lower limb amputation,
nephropathy, PAD, sex, and
smoking
T2D 2.1 (1.7-2.4)
12,372 DM without PDN Women 1.5 (1.4-1.6)
AlQuliti, 20152 Case control Saudi
Arabia
Foot examination and NSS $3 99 T2D with PDN Univariate analysis Age, CVD, diabetes duration,
glycaemic control, HbA1c,
hypertension, insulin use,
nephropathy, oral antidiabetic
drugs, PVD, retinopathy, sex,
smoking, stroke, and working
status
Age (.50 y) 1.93 (1.09-3.41)
99 T2D without PDN CVD 3.37 (1.28-8.89)
Diabetes duration (.10 y) 3.38 (1.88-6.07)
Glycaemic control 0.42 (0.12-0.96)
Hypertension 2.85 (1.57-5.17)
Nephropathy 8.93 (2.58-30.95)
Retinopathy 13.22 (4.49-
38.95)
Benbow et al.,
19974
Cross sectional UK Clinical history and examination;
burning/shooting pain/
hyperesthesia $6 mo and at
least 1 abnormal neurological
sign from decrease in light touch,
vibration, or pinprick sensation
49 DN with NP Univariate analysis Age, diabetes duration, diabetes
type, HbA1c, sex, and smoking
NA NA
23 DN without NP
Cheng et al.,
20105
Genetic case–control/
cross sectional
Taiwan Pain VAS $4 and grade 3-5 of
occurrence of pain in daily
activities
15 DFU (and DN) with NP Univariate analysis/
Fisher exact
Age, albumin, amputation, BMI,
diabetes duration, diabetes type,
haemoglobin, HbA1c,
hyperlipidemia, hypertension,
rs1799971 of OPRM1, and sex
rs1799971 0.24 (0.07-0.8)
50 DFU (and DN) without NP
Cortez et al.,
20146
Cross sectional Brazil DN4 $ 4 12 T2D with PDN Multivariate analysis Age, depressive symptoms,
diabetes duration, drug
adhesion, sex, and glycaemic
control
Diabetes duration P 5 0.031
60 T2D without PDN
D’Amato et al.,
20167
Cross sectional Italy DN4 $ 4 (DN4 interview $ 3) 25 DN with NP Multivariate analysis Depression Depression (BDI-II) 4.56 (1.09-19.1)
46 DN without NP
110 without DN
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Table 1 (continued)
Reference Study type Population Criteria for NP Sample size Analysis Variables analysed Predictors OR (95% CI)/P
Daousi et al.,
20048
Cross sectional UK Typical NP symptoms in legs$1
y, PSS$ 3 and NDS$ 6 or NDS
$ 3 and NSS $ 5
56 DM with PDN Univariate analysis Age, alcohol, angina, BMI, BP,
CVA, depression, diabetes
duration, diabetes type, foot
ulceration, HbA1c, hypertension,
MI, PVD, sex, and smoking
NA NA
289 DM without PDN
Davies et al.,
20069
Cross sectional UK Positive response to “Do you
have a burning, aching or
tenderness in your legs or feet?”
from DNSS and TCSS score .5
71 T2D with PDN (51 with NP and
20 with mixed NP and non-NP)
Univariate analysis Age, diabetes duration, HbA1c,
neuropathy severity, and sex
Severity of neuropathy P , 0.0001
99 T2D with non-NP
99 T2D with no pain
Erbas et al.,
201111
Cross sectional Turkey LANSS $ 12 156 DM with PDN Univariate analysis Age, blood urea BMI, BUN,
creatinine, diabetes duration,
diabetes type, FPG, HbA1c, PPG,
and sex
Duration of diabetes P 5 0.001
975 DM without PDN T1D P 5 0.039
Women P 5 0.001
Gore et al.,
200515
Cross sectional USA Physician diagnosed 255 with PDN Univariate analysis Anxiety, depression, enjoyment
of life, mental health, mood, and
relationship with others
Anxiety (HADS) All P , 0.05
Depression (HADS)
Enjoyment of life (BPI-DPN)
Mental health (SF-12v2)
Mood (BPI-DPN)
Relationship with others (BPI-
DPN)
Halawa et al.,
201017
Cross sectional Saudi
Arabia
DN4 $ 4 678 DM with PDN Univariate analysis Age, BMI, diabetes duration,
diabetes type, ethnicity,
smoking, and sex
Age P , 0.001
361 DM without PDN Diabetes duration P , 0.001
Women P 5 0.024
Harris et al.,
199318
Cross sectional USA Positive response to, “During the
past 3 mo, have you had a painful
sensation or tingling in your
hands or feet?”
2392 with DM (26.8% of whom
had pain/tingling in hands/feet?)
Multivariate logistic
regression
Age, amputation, angina,
diabetes age, diabetes duration,
ethnicity, family income, foot
sores, height, higher education,
hypertension, insulin,
nephropathy, obesity,
periodontal disease, proteinuria,
retinopathy, sex, smoking, and
stroke
Glycosuria 2.31 (1.54-3.47)
20,037 without DM Hyperglycaemia 2.51 (1.81-3.49)
Hypertension 1.58 (1.31-1.90)
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Table 1 (continued)
Reference Study type Population Criteria for NP Sample size Analysis Variables analysed Predictors OR (95% CI)/P
Jambart et al.,
201121
Cross sectional Middle East
Region
DN4 $ 4 2144 DM with PDN Multivariate
regression
Age, BMI, diabetes duration,
diabetes type, ethnicity, sex, and
smoking
Age (50-64 y) 1.75 (1.48-2.08)
1845 DM without PDN Age ($65 y) 2.13 (1.72-2.62)
BMI ($30 kg/m2) 1.35 (1.17-1.56)
Diabetes duration ($10 y) 2.43 (2.10-2.81)
Living in a Gulf State (compared
with Egypt)
0.44 (0.35-0.56)
Living in Lebanon (compared
with Egypt)
0.66 (0.54-0.81)
T1D 1.59 (1.24-2.05)
Women 1.27 (1.11-1.46)
Li et al., 201523 Genetic case control USA/
Canada
NCT00501202: lower extremity
pain $3 mo
887 DM with PDN Univariate analysis SNPs across SCN9A gene region rs74449889 (SCN9A) 2.6
NCT00870454: as above and
NRS-11 $11
1029 without DM and PDN rs3750904 (SCN9A) 2.2
NCT00993018: Symmetrical
pain beginning in feet.6 mo and
NRS-11 $5 but ,10 over 7 d.
rs4369876 (SCN9A) 2.1
NCT00455520: clinical
diagnosis with signs and
symptoms .6 mo and at
screening
rs12478318 (SCN9A) 2.1
NCT01041859: As
NCT00455520 and pain must
include reduction/absence of pin
sensibility
NCT01063868: As for
NCT00455520 and
NCT01041859 plus baseline
NRS-11 $4
Meng et al.,
201527
GWAS UK Prescription of at least one from
duloxetine, gabapentin,
pregabalin, capsaicin cream/
patch, and lidocaine patch. And
positive monofilament test in at
least 1 foot
572 DM with PDN Fisher exact SNPs across whole genome rs17428041 (Chr8p21.3) 0.67 (0.57-0.78)
2491 DM without PDN
Meng et al.,
201526
GWAS UK Multiple usage of at least 1 from
duloxetine, gabapentin,
pregabalin, capsaicin cream/
patch, lidocaine patch
961 DM with PDN Logistic regression SNPs across whole genome rs71647933 (Chr1p35.1) 2.31 (1.68-3.17)
3260 DM without PDN rs6986153 (Chr8p23.1) 1.67 (1.34-2.08)
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Table 1 (continued)
Reference Study type Population Criteria for NP Sample size Analysis Variables analysed Predictors OR (95% CI)/P
Purwata, 201130 Case control Indonesia Pain intensity VAS .0
(representing no pain)
59 DN with NP Univariate analysis Age, diabetes duration, FG,
HbA1c, iNOS expression, plasma
TNF-a, TNF-a expression, and
2h-G
iNOS expression 3.546 (1.613-
7.795)
51 DN without NP Plasma TNF-a 5.053 (2.241-
11.392)
TNF-a expression 4.125 (1.805-
9.425)
Sorensen et al.,
200232
Cross sectional Australia Bilateral and symmetrical foot
pain—patient specifically asked
about foot pain
2610 T2D (3.3% with PDN) Multivariate logistic
regression
Age, alcohol, diabetes duration,
diabetes treatment, ethnicity,
HbA1c, height, sex, and smoking
Diabetes Duration 1.09 (1.06-1.1)
Spallone et al.,
201133
Cross sectional Italy Clinical examination and history 78 DN with NP Multivariate logistic
regression
Age, alcohol, BMI, BP, creatinine,
CVD, diabetes duration, diabetes
type, HbA1c, HDL, hypertension,
LDL, nephropathy, PAD, physical
activity, retinopathy, sex,
smoking, triglyceride, and waist
circumference
BMI (kg/m2) 1.22 (1.08-1.37)
57 DN without NP Severity of neuropathy 1.27 (1.11-1.44)
56 without DN or NP
Themistocleous
et al., 201636
Cross sectional UK IASP/NeuPSIG grading system 70 DPN with moderate/severe
NP
Univariate analysis Age, BMI, diabetes duration,
diabetes type, ethnicity, HbA1c,
neuropathy severity, orthostatic
hypotension, ratio, sex, standing
and lying BP, and waist–hip
circumference
HbA1c and neuropathy severity P , 0.01
41 DPN with mild NP P , 0.01
80 DPN without NP
Van Acker et al.,
200938
Cross sectional Belgium DN4 $ 4 and positive Neuropen
test
157 DN with NP Multivariate logistic
regression
Age, BMI, BP, diabetes duration,
foot lesions, HbA1c, HDL, insulin,
LDL, nephropathy, retinopathy,
sex, triglycerides, and waist
circumference
Age (per 10 y) 1.47 (1.20-1.81)
321 DN without NP Diabetes duration (per 5 y) 1.14 (1.02-1.28)
HDL cholesterol (#1 mmol/L for
men, #1.3 mmol/L for women)
2.17 (1.38-3.41)
Nephropathy 1.69 (1.10-2.59)
Obesity ($30 kg/m2) 1.62 (1.05-2.49)
Triglycerides ($1.7 mmol/L) 1.76 (1.13-2.75)
Wu et al., 200741 Cross sectional France MNSI $ 7 and Q5 of BPI $ 1 72 DN with NP No statistical
analysis
Age, diabetes age, diabetes
duration, diabetes type,
education, employment, region,
and sex
Age (over 65 y) NA
12 DN without NP Men
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2.4. Genetics
Numerous published studies have found that both T1D and T2D
have a heritable component3,19,29,31 and genetic studies have
been conducted in DN,24,34 although heritability studies have yet
to be conducted. A heritable component to PDN has been hinted
at in 1 study, which found that 56% of participants also reported
a family member with the condition.14 Two PDN genome-wide
association studies have been conducted, both in the same
Scottish diabetic cohort, but with slightly differing phenotype
definitions. The first used a positive monofilament test combined
with a prescription history of at least 1 from 5 recommended NP
medicines. This yielded an association at chromosome 8p21.3
near the geneGFRA2 and estimated the narrow-sense heritability
(proportion of phenotypic variance explained by additive genetic
variance) to be 11%.27 The second used the same definition but
without the monofilament test and aimed to capture associations
that may have been missed in the previous study, using a less
specific cohort. This found sex-specific associations at chromo-
some 1p35.1 in the ZSCAN20/TLR12P gene regions in females
and chromosome 8p23.1 next to HMGB1P46 in males.26 The
narrow-sense heritability was 30% in males and 14.7% in
females. In both of these studies, controls were defined as
patients who had not previously been prescribed any of the 5 NP
medicines or other medicines which are predominantly pre-
scribed for other conditions but are also known to be prescribed
for NP. Two separate candidate-gene studies have been
conducted and have reported associations with PDN. The first
was in the sodium channel gene SCN9A, which is expressed in
dorsal root ganglia, using a combination of numerical rating
scales and clinical examinations to compare PDN with healthy
controls.23 The second was in the opioid receptor gene OPRM1
using a visual analogue scale for pain intensity and a grading
system for pain occurrence during daily activities.5 All 4 of these
studies require independent replication, and further studies are
required to establish the extent to which genetics contribute
specific risk of PDN and the mechanism of this contribution.
3. Conclusions
Despite the limited number of studies reporting specific predictors
for PDN, clear similarities are emergingwith the knowngeneral risk
factors for both DM andDN. These include clinical factors such as
diabetes type andduration and lifestyle factors such as bodymass
index andwaist circumference, some ofwhich are not easily or not
at all modifiable. Although further work is needed, this suggests
that PDN is a manifestation of longer-lasting and more severe
diabetes and certainly that it requires specific testing and
diagnosis in routine diabetic care. However, there are likely to be
factors, among those with DM (with and without DN) that confer
a greater risk of PDN, and these require further exploration. It
should be noted that while the published literature (and this topical
review) hasmainly explored NP arising from DN, NP can also arise
in the diabetic population through other causes, for example,
sciatic neuralgia and carpal tunnel syndrome. The influence of
diabetes on the development of NP in these conditions is an area
that requires further investigation. There is clear evidence to
suggest PDN has a negative impact on quality of life; however, the
extent to which the reverse is true—bidirectional aetiology—is
currently unknown. Future studies need to be conducted in
a longitudinal manner or as clinical trials to establish the temporal
relationship between variable and disease, particularly with
respect to identifying specific PDN risk factors in T1D and T2D
patients. The previous point can be further strengthened by
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running Mendelian randomization studies, something that has
been used in DM.16 Mendelian randomization studies establish
causal relationship by comparing 2 groups of individuals with and
without a genetic marker known to influence the variable being
studied. As genotype assignment is random and not subject to
confounding typically found in epidemiological studies, a higher
prevalence of disease in the group with the marker implies
causality. However, we would first need clearer evidence to
identify genetic factors associatedwith PDN. Finally, greater clarity
is needed in specifying whether painful or nonpainful DN is being
analysed. This can be enhanced by forming a consensus on PDN
phenotype definition, to enable studies to be more comparable
with one another. This is something that has been addressed for
NP generally and could also be applied to PDN.40 This would
make replication of results more likely and brings the added
potential of being able to perform meta-analyses in the future. All
these limitations will be addressed in the DOLORisk study (http://
dolorisk.eu/), a European consortium which aims to identify risk
factors for NP.
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